Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Media Coverage
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Media Coverage
Enveric Biosciences Receives Two US Patents for Psilocybin Derivatives [Microdose]
December 3, 2024
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results [Benzinga]
November 25, 2024
Enveric inks $62M licensing deal for psilocin prodrug [Green Market Report]
November 12, 2024
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal [Benzinga]
November 12, 2024
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions [Benzinga]
November 4, 2024
Enveric Biosciences Unveils Positive Safety and Pharmacology Data for EB-003 [Microdose]
October 15, 2024
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies [Benzinga]
October 8, 2024
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit [Microdose]
September 25, 2024
Enveric Biosciences Presents Compelling Preclinical Data On Lead Compound EB-003 At 7th Neuropsychiatric Drug Summit [Benzinga]
September 25, 2024
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences’ Breakthrough Research [Benzinga]
September 25, 2024
1
2
3
…
12
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
